Enabling scalable and affordable cell therapy manufacturing.
A closed, automated and sensor-enabled workflow that consolidates multiple unit processes into a single core consumable — reducing facility footprint, simplifying operations and lowering cost of goods.
Scalable and affordable autologous cell therapy remains out of reach.
Today's manufacturing is fragmented, manual and capital-intensive — limiting patient access.
Platform Complexity
Current workflows rely on up to 8 standalone instruments, creating fragmented processes and inefficiencies.
Batch Failures
Open, manual processes contribute to >10% batch failures, increasing risk and cost.
Labour Input
Manual intervention drives 25–51% of batch costs and limits scalability.
Facility Costs
Cleanroom buildouts exceed $1,000 per square foot — a major barrier to scale and affordability.
One closed consumable. Every unit process.
Solupore® Integrated redefines the architecture of cell therapy manufacturing — replacing racks of standalone instruments with a modular, automated platform built around a single GMP consumable.
Integrated Processes
Activation, transduction, expansion and harvest — consolidated into one core consumable.
Scale-Out Architecture
Smaller, lighter automated units integrate into existing workflows for parallel batch processing.
Closed & Automated
Automated sampling and in-line pH/DO and CO₂ sensors deliver full process monitoring and data integrity.
Cost-Effective Growth
Densification and scale-out reduce footprint and labour, driving significant COGS reductions.
Higher throughput from a smaller footprint.
Traditional integrated platforms process one batch per run. Solupore® Integrated runs in parallel — increasing throughput while reducing required space.
Annual Platform Throughput
+600%batches / year
Facility Investment
−75%relative capex
High throughput without compromising quality.
Solupore® Integrated consistently produces large numbers of potent CAR-T cells. Representative sample data for a 7-day process:
Potent cells. Preserved phenotype.
Solupore® Integrated yields a product that retains a stem-like phenotype and shows minimal T-cell exhaustion.
Stem-like phenotype
Cells maintain a Tscm / Tcm phenotype associated with long-term persistence.
Low exhaustion
Low expression of PD-1, LAG-3 and TIGIT supports durable function.
Potent cytotoxicity
Highly cytotoxic at multiple effector-to-target ratios with strong IFNγ release.
Rapid expansion
Rapid expansion within 7 days without compromising cell quality.
Non-viral editing and expansion — in one closed consumable.
The integrated transfection-expansion workflow simplifies complex engineering tasks while preserving cell quality across mRNA, CRISPR and HDR programs.
Discuss Your ApplicationHigh editing efficiency with minimal perturbation, Day 3.
Large total viable cell output, Day 7.
Editing maintains phenotype and viability.
Supports mRNA, CRISPR and HDR workflows.
Built for GMP from day one.
Regulatory
GMP consumable with a Drug Master File (DMF) filed with the FDA.
Digitalisation
Automated sampling, in-line pH/DO sensing and 21 CFR Part 11 electronic run record.
Supply Chain
US-established supply chain with qualified suppliers for reliability and rapid deployment.
Technology Transfer
Engineered for smooth scale-up from RUO into full GMP manufacturing.
Lower cost of goods. Broader patient access.
Solupore® Integrated reduces total cell therapy manufacturing cost through lower facility investment, lower labour and fewer failure-related expenses — while increasing throughput.
- Labour Savings. Automation and process integration reduce labour inputs, cutting COGS by up to 25%.
- Scalable Economics. Densification and parallel-processing AMUs lower facility investment by up to 75%.
*Based on comparative analysis of equipment costs, labour inputs and facility utilisation versus integrated single-batch platforms.
"It's estimated that only between 15% to 20% of patients who could potentially benefit from CAR-T cell therapy are actually receiving it."
Ready to transform cell therapy manufacturing?
Partner with Avectas to bring scalable, high-quality therapies to patients worldwide.